Grufity logo
Grufity logo
CYTH

CYTH - Cyclo Therapeutics, Inc. Stock Price, Fair Value and News

$7.44+0.21 (+2.90%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

3/100

CYTH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

3/100

CYTH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CYTH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYTH Price Action

Last 7 days

-8.4%

Last 30 days

-16.7%

Last 90 days

24.7%

Trailing 12 Months

106.6%

CYTH RSI Chart

CYTH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYTH Valuation

Market Cap

258.3M

Price/Earnings (Trailing)

-10.42

Price/Sales (Trailing)

296.69

EV/EBITDA

-10.41

Price/Free Cashflow

-11.47

CYTH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CYTH Fundamentals

CYTH Revenue

CYTH Earnings

CYTH Profitability

Free Cashflow Yield

-8.72%

CYTH Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20241.1M1.1M870.7K-
20231.3M908.5K951.8K1.1M
20221.4M1.7M1.8M1.4M
2021935.8K964.8K1.1M1.6M
20201.1M1.0M985.2K903.4K
20191.0M957.9K1.0M1.0M
20181.1M957.1K940.4K1.0M
20171.5M1.6M1.6M1.2M
20161.1M1.1M1.1M1.5M
20151.2M1.4M1.2M950.5K
20141.7M1.1M1.4M1.6M
20131.2M1.7M1.8M1.7M
20121.2M941.3K867.4K988.0K
2011853.0K912.6K972.2K1.0M
2010---793.4K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Cyclo Therapeutics, Inc.

CYTH
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
 CEO
 WEBSITEhttps://cyclotherapeutics.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES9

Cyclo Therapeutics, Inc. Frequently Asked Questions

CYTH is the stock ticker symbol of Cyclo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Cyclo Therapeutics, Inc. is 258.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, CYTH's PE ratio (Price to Earnings) is -10.42 and Price to Sales (PS) ratio is 296.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYTH PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Cyclo Therapeutics, Inc. has provided -0.105 (multiply by 100 for percentage) rate of return.